Skip to content

Press Releases

Updates on ProBioGen and cover currently relevant topics on human biopharmaceuticals, notably on therapeutic proteins and viral vaccines. 

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
vaccine development license cancer

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Nov 5, 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
CDMO development antibody

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

May 29, 2024

Change in Management
leadership

Change in Management

Apr 30, 2024

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
partnership multivalent vaccine hemorrhagic fever

ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever

Mar 27, 2024

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
partnership antibody GlymaxX Marburg Virus

ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology

Mar 13, 2024

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology
technology new patent transposase

ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology

Dec 14, 2023

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
vaccine development license

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

Sep 26, 2023

ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™
launch lentivirus manufacturing new technology

ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™

May 17, 2023

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform
manufacturing clinical phase vaccine

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

May 4, 2023

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
partnership cancer treatment

ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients

Apr 12, 2023

ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023
growth performance

ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023

Mar 30, 2023

ProBioGen’s Growth Strategy Continues Successfully
growth leadership

ProBioGen’s Growth Strategy Continues Successfully

Mar 2, 2023

Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III

Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III

Jan 26, 2023

ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production

ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production

Jan 18, 2023

ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology

ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology

Jan 10, 2023

Press Contact

probiogen-sarah-wandrey

Sarah Wandrey

Corporate Communications

Phone: +49 (0) 30 3229 35 144
Email: press@probiogen.de

ProBioGen News 

Join our news and always be up-to-date.

Subscribe